p53 and brain tumors: From gene mutations to gene therapy

Brain Pathology

Volumn 8, Issue 4, 1998, Pages 599-613

  Fulci, Giulia ^a,b   Ishii, Nobuaki ^a   Van Meir, Erwin G ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ANGIOGENESIS; APOPTOSIS; BRAIN TUMOR; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL GROWTH; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GROWTH REGULATION; REVIEW; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 0031705691     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1998.tb00187.x     Document Type: Review

References (128)

1. Aas AT, Tonnessen TI, Brun A, Salford LG (1995) Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. J. Neuro-Oncol. 24: 171-80
2. Agarwa; ML, Agarwal A, Taylor WR, Stark GR (1995) p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA. 92: 8493-7
3. Albertoni M, Daub DM, Arden KC, Viars CS, Powell C, Van Meir EG (1998) Genetic instability leads to loss of botri p53 alleles in a human glioblastoma. Oncogene. 16: 321-326
4. Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT, Oldfield EH (1994) Heterogeneity of subcellular localization of p53 protein in human glioblastomas. Cancer Res. 54:1-5
5. Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong SH, Takamoto S, Nomura K, Matsutani M, Takakura K, Kuchino Y (1994) Negative effects of wild-type p53 and s-Myc on cellular growth and tumongenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J. Neuro-Oncol. 19: 259-68
6. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell. 89: 1175-84
7. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL (1995) Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neuro. Res. 17: 209-16
8. Baldwin NG, Rice CD, Tuttle TM, Bear HD, Hirsch JI. Merchant RE (1997) Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes. J. Neuro-Oncol. 32: 19-28
9. Beckman WJ, Powers SK, Brown JT, Gillespie GY, Bigner DD, Camps JJ (1987) Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo. Cancer. 59: 266-70
10. Benda P, Someda K, Messer J, Sweet WH (1971) Morphological and immunochemical studies of rat glial tumors and clonal strains propagated in culture. J. Neurosurg. 34: 310-23
11. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC (1996) p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int. J. Cancer. 69: 190-2
12. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1: 1029-34
13. Bertrand P, Rouillard D, Boulet A, Levalois C, Soussi T, Lopez BS (1997) Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. Oncogens. 14: 1117-1122
14. Bögler O, Huang HJS, Cavenee WK (1995) Loss of wildtype p53 bestows a growth advantage on primary cortical astrocytes and facilitates their in vitro transformation. Cancer Res. 55: 2746- 51
15. Bögler O, Huang HJS, Kleihues P, Cavenee WK (1995) The p53 gene and its role in human brain tumors. Glia. 15: 308-27
16. Boulikas T (1996) Liposome DNA delivery and uptake by cells. Oncol. Rep. 3: 989-995
17. Brown CR, Doxsey SJ, White E, Welch WJ (1994) Both viral (adenovirus E1B) and cellular (hsp 70, p53) components interact with centrosomes. J. Cell Physiol. 160: 47-60
18. Caelles C, Helmberg A, Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 370: 220-3
19. Chen J, Willingham T, Shuford M, Bruce D, Rushing E, Smith Y, Nisen PD (1996) Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene. 13: 1395-403
20. Chen Y, Chen PL, Lee WH (1994) Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol. Cell. Biol. 14: 6764-72
21. Cho Y Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355
22. Crafts D, Wilson CB (1977) Animal models of brain tumors. Natl. Canc. Inst. Mon. 46: 11-7
23. Cross SM, Sanchez CA. Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ (1995) A p53-dependent mouse spindle checkpoint. Science. 267: 1353-6
24. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibre-blasts by p53 regulation of thrombospondin-1. Science. 265: 1582-4
25. Davis FG, Preston-Martin S (1998) Epidemiology. In: RUSSELL AND RUBINSTEIN'S Pathology of Tumors of the Nervous Sytem, Bigner DD, McLendon RE, Bruner JM, 17-33, London
26. Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 274: 430-2
27. Di Leonardo A, Khan SH, Linke SP, Greco V, Seidita G, Wahl GM (1997) DNA rereplication in the presence of mitotic spindle inhibitors in human and mouse fibroblasts lacking either p53 or pRb function. Cancer Res. 57: 1013-1019
28. Di Leonardo A, Linke SP, Clarkin K, Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Develop. 8: 2540-51
29. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993) Gain of function mutations in p53. Nature Genet 4: 42-46
30. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) WAF1, a potential mediator of p53 suppression. Cell. 75:817-825
31. Fujiwara T, Mukhopadhyay T, Cai DW, Morris DK, Roth JA, Grimm EA(1994) Retroviral-mediated transduction of p53 gene increases TGF-beta expression in a human glioblastoma cell line. Int. J. Cancer. 56: 834-9
32. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude G (1996) Abnormal centrosome amplification in the absence of p53. Science. 271: 1744-7
33. Goh HS, Yao J, Smith DR (1995) p53 point mutation and survival in colorectal cancer patients. Cancer Res. 55: 5217-21
34. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-78
35. Haas-Kogan D, Yount G, Haas M, Levi D, Kogan SS, Hu L, Vidair C, Deen DF, Dewey WC, Israel MA (1996) p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int. J. Radiat. Oncol Biol. Phys. 36: 95-103
36. Hamaut P, Soussi T, Shomer B, Hollstein M, Greenblatt M, Hovig E, Harris CC, Montesano R (1997) Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucl. Ac. Res. 25: 151-7
37. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein is a potent inhibitor of G1 cyclin-dependent kinases Cell 75: 805-816
38. Harvey M, Voget H. Morris D. Bradley A, Bernstein A, Donehower LA (1995) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genet. 9: 305-11
39. Haupt Y, Barak Y. Oren M (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 15: 1596-606
40. Haupt Y, Rowan S, Oren M (1995) p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene. 10: 1563-71
41. Hayashi Y, Yamashita J, Yamaguchi K (1991) Timing and roie of p53 gene mutation in the recurrence of glioma. Biochem. Biophys. Res. Comm. 180: 1145-1150
42. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff D, Kim DH (1997) ONYX-015, an E1B geneattenuated adenovirus. causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 3: 639-45
43. Hiraga S, Arita N, Ohnishi T, Izumoto S, Taki T, Higuchi M, Iwaisako K, Sakoda S, Yamamoto Y Hayakawa T (1996) Establishment of spontaneously immortalized rat type 1 astroglial cell lies: the role of p53 in astroglial carcinogenesis. Glia. 18: 185-99
44. Hiraga S, Arita N, Ohnishi T, Izumoto S, Taki T, Yamamoto H, Higuchi M, Hayakawa T (1995) Transformation of type 1 astrocytes with N-ethyl-N-nitrosourea: establishment of an in vitro system and the role of the p53 gene. Glia. 13: 51-63
45. Holtstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucl. Ac. Res. 24: 141-6
46. Hono Y, Takahasni T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R, et al (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 53: 1-4
47. Hsiao M, Tse V, Carmel J, Costanzi E, Strauss B, Haas M, Silverberg GD (1997) Functional expression of human p21(WAFl/CIP1) gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity. Biochem. Biophys. Res. Comm. 233: 329-35
48. Hsiao M, Tse V, Carmel J, Tsai Y, Feigner PL, Haas M, Silverberg GD (1997) Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wildtype p53 in vivo results in tumor suppression and long-term survival. Biochem. Biophys. Res. Comm. 233: 359-364
49. Imamura J, Bartram CR, Berthold F, Harms D, Nakamura H, Koeffler HP (1993) Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res. 53: 4053-8
50. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M, Sakiyama S (1996) Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int. J. Cancer. 69: 236-40
51. Jung JM, Li H, Kobayashi T, Kyritsis AP, Langford LA. Bruner JM, Levin VA, Zhang W (1995) Inhibition of human giiobiastoma cell growth by WAF1/Cip1 can be attenuated by mutant p53. Cell Growth Differ. 6: 909-13
52. Kieser A, Weich HA, Brandner G, Marme D, Kolch W (1994) Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 9: 963-9
53. Kleihues P, Aguzzi A, Ohgaki H (1995) Genetic and environmental factors in the etiology of human brain tumors. Toxicol. Lett. 3: 601-605
54. Kleihues P, Ohgaki H, Eibl RH, Reichel MB, Mariani L, Gehnng M, Petersen l, Hol! T, von Deimling A, Wiestler OD, et al. (1994) Type and frequency of p53 mutations in tumors of the nervous system and its coverings. Recent Results Cancer Res. 135: 25-31
55. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. Am. J. Pathol. 150: 1-13
56. Ko LJ, Prives C (1996) P53 - Puzzle and Paradigm. Genes Develop. 10: 1054-1072
57. Kock H, Harris MP, Anderson SC, Machemer T, Hancock W, Sutjipto S, Wills KM, Gregory RJ, Shepard HM, Westphal M, Maneval DC (1996) Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo. int. J. Cancer. 67: 808-15
58. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji R, Peterson JW, Werbet B, Barnett GH (1996) WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene. 13: 1279-85
59. Kyritsis AP, Yung WK, Leeds NE, Bruner J, Gleason MJ, Levin VA (1992) Multifocal cerebral gliomas associated with secondary malignancies. Lancet. 339: 1229-30
60. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell. 88: 323-31
61. Li HW, Lochmuller H, Yong VW, Karpati G, Nalbantoglu J (1997) Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J. Neuropath. Exp. Neur. 56: 872-878
62. Li J, Hu SX, Perng GS, Zhou Y, Xu K, Zhang C, Seigne J, Benedict WF, Xu HJ (1996) Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro. Oncogene. 13: 2379-86
63. Lin D, Shields MT, Ullrich SJ, Appella E, Mercer WE (1992) Growth arrest induced by wild-type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc. Natl. Acad. Sci. USA. 89: 9210-4
64. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70: 923-35
65. Lotem J, Sachs L (1995) A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity. Proc. Natl. Acad. Sci. USA. 92: 9672-6
66. Lowe SW, Bodis S, McClatchey A, Remington L. Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 Status and the efficacy of cancer therapy in vivo. Science. 266: 807-10
67. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, de Fromentel CC, Preudhomme C, Fenaux P, Fournier G, et al (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface Cancer Res. 53: 5872-6
68. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T (1995) Serum p53 antibodies as early markers of lung cancer. Nat. Med. 1: 701-2
69. Ludes MJ, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S (1996) Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol. Cell. Biol. 16: 6009-19
70. Margulies L, Sehgaf PB (1993) Modulation of the human inierleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species. J. Biol. Chem. 268: 15096-100
71. Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Carroll D, Brodsky I, Haines DS (1997) Altered expression of p53 and mdm-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia. J. Clin. Oncol. 15: 1158-62
72. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F (1992) p53 expression and prognosis in gastric carcinoma. Int. J. Cancer. 50: 859-62
73. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB (1996) Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183: 1357-65
74. Mekeel KL, Tang W, Kachnic LA, Luo CM, Defrank JS, Powell SN (1997) inactivation of p53 results in high rates of homologous recombination. Oncogene. 14: 1847-1857
75. Mercer WE, Shields MT, Amin M, Sauve GJ, Appella E, Romano JW, Ullrich SJ (1990) Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. USA. 87: 6166-6170
76. Mercer WE, Shields MT, Lin D, Appella E. Ullrich SJ (1991) Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA. 88: 1958-1962
77. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9: 1799-805
78. Miyashita T, Reed JC (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80: 293-9
79. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA (1996) Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J. Thorac. Cardiov. Sur. 112: 1372-6
80. Nishimori H, Shiratsuchi T, Urano T, Kimura Y, Kiyono K, Tatsumi K, Yoshida S, Ono M, Kuwano M, Nakamura Y, Tokino T (1997) A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene. 15: 2145-2150
81. Ohgaki H, Eibl RH, Schwab M, Reichel MB, Mariani L, Gehring M. Petersen I, Holl T. Wiestler OD, Kleihues P (1993) Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog. 8: 74-80
82. Ory K, Legros Y, Auguin C, Soussi T (1994) Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13: 3496-504
83. Plate KH, Breier G, Weich HA, Mennel HD, Risau W (1994) Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 59: 520-9
84. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM (1997) The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res. 57: 304-9
85. Potyak K, Waldman T, He TC, Kinzler KW, Vogelstein B (1996) Genetic determinants of p53-induced apoptosis and growth arrest. Genes Develop. 10: 1945-52
86. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature. 389: 300-305
87. Ramov NG, Dobberstein KU, Bahn H, Holzhausen HJ, Lautenschlager C, Heidecke V, Burkert W (1997) Prognostic factors in malignant glioma : Influence of the overexpression of oncogene and tumor-suppressor gene products on survival. J. Neuro-Oncol. 35: 13-28
88. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53: 2736-9
89. Rice CD, Baldwin NG, Biron RT, Bear HD, Merchant RE (1997) Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes. J. Neuro-Oncol. 32: 29-38
90. Righetti SC, Della TG, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56: 689-93
91. Rolley N, Butcher S, Milner J (1995) Specific DNA binding by different classes of human p53 mutants. Oncogene. 11: 763-70
92. Ropke M, Hald J, Guldberg P, Zeuttien J, Norgaard L, Fugger L, Svejgaard A, Van Der Burg, S, Nijman HW, Melief CJ, Claesson MH (1996) Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA. 93: 14704-7
93. Sakamuro D, Sabbatini P, White E, Prendergast GC (1997) The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 15: 887-98
94. Salcman M (1995) The natural history of low-grade gliomas. In: Benign Cerebral Glioma, M.L.J. A, 213-229, Illinois
95. Sandig V, Brand K, Herwig S, Lukas J, Bartek J, Strauss M (1997) Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med. 3: 313-9
96. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 52: 6380-4
97. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88: 593-602
98. Shelling AN (1997) Role of p53 in drug resistance in ovarian cancer. Lancet. 349: 744-5
99. Shin TH, Paterson AJ, Kudlow JE (1995) p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53. Mol. Cell. Biol. 15: 4694-701
100. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavenee W, Vogelstein B (1992) Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 355: 846-7
101. Sjögren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L, Bergh J (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Canc. Inst. 88: 173-82
102. Srivastava S, Wang S, Tong YA, Hao ZM, Chang EH (1993) Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis. Cancer Res. 53: 4452-5
103. Stewart N, Hicks GG, Paraskevas F, Mowat M (1995) Evidence for a second cell cycle block at G2/M by p53. Oncogene. 10: 109-15
104. Sturzbecher HW, Donzelmann B, Henning W, Knippschild U, Buchhop S (1996) p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J. 15: 1992-2002
105. Tada M, Iggo RD, Ishii N, Shinohe Y, Sakuma S, Estreicher A, Sawamura Y, Abe H (1996) Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int J. Cancer. 67: 447-50
106. Tada M, Iggo RD, Wandel R Nozaki M, Matsumoto R, Sawamura Y, Shinohe Y, Ikeda J, Abe H (1997) Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses. Mol. Carcin. 18: 171-6
107. Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, Shinohe Y (1998) Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 58: 1793-1797
108. Tenan M, Carrara F, Di Donato S, Finocchiaro G (1995) Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CKI gene in malignant gliomas. Int J Cancer. 62: 115-7
109. Ueba T, Nosaka T, Takahashi JA, Shibata F, Florkiewicz RZ, Vogelstein B, Oda Y, Kikuchi H, Hatanaka M (1994) Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. USA. 91: 9009-13
110. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang H-JS, Friedmann T, de Tribolet N, Cavenee WK (1994) Analysis of the p53 gene and its expression in human glioblastoma celts. Cancer Res. 54: 649-52
111. Van Meir EG, Polverini PJ, Chazin VR, Huang H-JS, de Tribolet N, Cavenee WK (1994) Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in gliobiastoma cells. Nature Genet. 8: 171-6
112. Van Meir EG, Roerner K, Diserens AC, Kikuchi T, Rempel SA, Haas M, Huang H-JS, Friedmann T, de Tribolet N, Cavenee WK (1995) Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc Natl Acad Sci U S A. 92: 1008-12
113. Van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG (1994) p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. J. Natl. Canc. Inst. 86: 1011-7
114. Vierboom MP, Nijman HW, Offringa R, van Der Voort EI, van Hall T, van Den Broek L, Fleuren GJ, Kenemans P, Kast WM, Melief CJ (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186: 695-704
115. Volpert OV, Dameron KM, Bouck N (1997) Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene. 14: 1495-502
116. Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF, Bouck N (1995) Inhibition of angiogenesis by thrombospondin-2. Biochem. Biophys. Res. Comm. 217: 326-32
117. von Deimling A, Eibl RH, Ohgaki H, Louis DN, von Ammon K, Petersen I, Kleihues P, Chung RY, Wiestler OD, Seizinger BR (1992) p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res. 52: 2987-90
118. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN (1993) Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol. 3: 19-26
119. Walker KK, Levine AJ (1996) Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Pros. Natl. Acad. Sci. USA. 93: 15335-40
120. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, Wang Z, Freidberg EC, Evans MK, Taffe BG, et al (1995) p53 modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet. 10: 188-95
121. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 6: 217-23
122. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H (1997) Role of gemistocytes in astrocytoma progression. Lab. Invest. 76: 277-84
123. Werner H, Karnieli E, Rauscher FJ, LeRoith D (1996) Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc. Natl. Acad. Sci. USA. 93: 8318-23
124. Williams AC, Miller JC, Collard TJ, Bracey TS, Cosulich S, Paraskeva C (1995) Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation. Oncogene. 11: 141-9
125. Yahanda AM, Bruner JM, Donehower LA, Morrison RS (1995) Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol. Cell. Biol. 15: 4249-59
126. Yanuck M, Carbone DP. Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA (1993) A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res. 53: 3257-61
127. Yount GL, Haas KD, Vidair CA, Haas M, Dewey WC, Israel MA (1996) Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res. 56: 500-6
128. Zhang YP, Xiong Y, Yarbrough WG (1998) ARF promotes mdm2 degradation and stabilizes p53 - ARF-INK4a locus deletion impairs both the rb and p53 tumor suppression pathways. Cell. 92: 725-734